This expert panel statement provide recommendations for use of IDegAsp in clinical practice for different patient populations (T1D, T2D, children, adults, pregnant, elderly, hospitalized patients) and for varying practice patterns (insulin-naive, insulin-treated, switching from basal, basal bolus and premix regimens) to assist clinicians in using this novel insulin regimen in clinical practice. This evidence concerns the gene INS and type 2 diabetes mellitus.